upgrad buy hcv stori hiv
tough sinc believ worst gener move
behind hcv co buysid expect sentiment
alreadi low see better day ahead year declin consensu ep
re-grow want come declin
back recoveri period
fundament sentiment improv u-shap recoveri think
upcom guidanc like low hcv surpris
consensu buysid expect mostli alreadi hcv longer
big thesi stock shift move beyond hep franchis
come done lot work see could re-grow earn
next year turn stori around risk/reward look good upsid
busi stabil new pipelin play w/ posit surpris vs
busi remain uncertain year see dcf scenario model insid expect
stock move higher investor return optimist view cheap call option
pipelin come
deep dive work catalyst new franchis see new
b/f/taf hiv approv feb good launch gsk gemini doublet data come
soon probabl play major threat see full hiv deep dive analysi
report discuss issu market kite yescarta launch fine
importantli underli demand w/ center plenti pt
logist catch host call et contact
sale dial-in also bcma myeloma data year could surpris
baracitinib pdufa mid-year phase filgotinib ra data come shine light
valu phase nash cirrhot data earli expect
email us nash work model
bear case earli call comfort hcv take share could cut price car-
launch could disappoint spent juno nv come roch
polatuzumab data look good dlbcl market jak nash
far away need deal still cheap
pt base ep risk pt includ price pressur competit
hiv gener launch pipelin disappoint
hold
pleas see analyst certif import disclosur inform inform regard statu non-u analyst page report
pt base view remain
cheap low-expect stori around
earn revenu earn could flat
declin next year
analysi suggest durabl hiv busi along
importantli includ string-of-
pearl type bolt-on continu build mid/lat
stage pipelin improv visibl
upsid scenario price base appli
multipl non-gaap ep estim
dcf base busi pipelin product
upsid target base durabl hiv busi
remain flattish instead declin post
could see multipl expans near-term
stabil and/or growth hep franchis
upsid posit data readout pipelin program
nash hep oncolog
believ continu
potenti gene therapy/ gene edit space
believ gild hiv franchis could durabl
believ hcv busi increas visibl
becom manag pricing/volum
turn page sever near-
term driver grind higher
guidanc given feb
conserv may remov overhang
phase ii nash psc data fxr
launch new hiv b/f/taf feb
gsk gemini studi show dtg doublet good
baricitinib launch filgotinib ra data
robust yescarta launch
phase nash data
yescarta launch goe better expect
downsid scenario base appli
multipl non-gaap ep estim
yescarta launch could miss analyst estim
viread face new gener particularli eu start
hcv franchis like face price pressur
new effect hcv regimen
gsk could take increas market share hiv base
page
pleas see import disclosur inform page report
tabl content
thought gild hcv franchis
thought gild hiv franchis
feb pdufa b/f/taf
treatment-nav patient b/f/taf show non-inferior triumeq dtg f/taf
studi
thought b/f/taf
statu sword gemini studi
treatment-nav patient data expect file
paddl studi support rational gemini week data juli ia
phase ii studi build paddl week result juli ia
potenti long-act oral drug current phase iib
histor project incom statement
histor project balanc sheet
histor project
page
pleas see import disclosur inform page report
picturehcv estim eventu get realist number
stock challeng wide rang estim
hcv dynam
fresh competit price pressur make
revenue/earn consensu volatil last two year hcv consensu
gone lower think consensu
get closer number next quarter compani report
competit stabl guidanc given feb
like conserv may remov overhang bullish investor
would like consensu come attent could turn yescarta car-t
phase filgotinib phase nash data
result still see step-down hcv view
lead hcv estim closer number meanwhil consensu
turn start get investor get comfort hcv
consensu time potenti strong yescarta launch
ownabl stock continu recov also offer pipelin call
option nash filgotinib
compon drive stock month
yescarta car-t launch good ramp site
compani reiter comfort reimburs drg code medicar
ok first year big cancer hospit exempt drg model
increas attent pipelin jak filgotinib could becom best class
better safeti competitor manag believ potenti class risk
thrombosi lower filgotinib given hit on-going event rate
suggest vt risk lower expect other also phase nash data start
see perhap chanc work base mix phase ii data though
page
pleas see import disclosur inform page report
hcv competit may stabl
hcv consensu number may come attent shift yescarta
hep sale lack visibl go forward stabil and/or growth
franchis could suggest earn result consensu expect shift
compani valuat toward upsid
sever pipelin asset develop nash hep liver
indic posit data readout candid provid
investor confid gild abil diversifi sustain long-term revenu
hiv continu perform better expect potenti approv
bictegravir hiv patient could help franchis fend competit
gsk believ gild hiv busi could worth one
assum revenu remain flattish moder grow versu declin
due dolutegravir competit
yescarta car-t launch reimburs seem achiev first year
engag sever deal post kite acquisit next month
near yield amongst largest balanc sheet capabl biotech
plenti deal
top notch manag team weather storm like
make strong strateg decis find growth next year
largest nash pipelin multipl shot goal matter time
given essenti zero credit consensu
glpg phase filgotinib could end drug best-in-class
crohn data possibl best busi far jak filgotinib safeti
debat co said feel good filgotinib low end
thrombosi rate vs competitor look rate per total patient
hire new head oncolog kite acquisit
guidanc given end januari like conserv may
remov overhang
hcv still face downward pressur stabil take longer
expect hasnt seen full effect competitor mavyret yet
script keep grow grow take share
still market variou new hcv regimen includ gt
hcv price expect go bottom price
know
valu investor wont step hcv bottom manag
deal commentari doesnt suggest hcv go bottom anytim immedi
would payor open access
hiv also risk/vis issu due dtg two-drug regimen hiv unclear
gsk doublet dolutegravir pill could come compet price
allogen car-t off-the-shelf remain risk factor data play data yet
good though
may start launch care ensur top center run safeti
issu therefor may initi tepid/cauti launch
movement gild stock hing launch axil-cel
launch slower expect
page
pleas see import disclosur inform page report
revenu initi kite launch increment first year
still declin revenu overal would need deal
glpg jak may issu delay fda tough got
market jak clear differenti abil leverag volum payor
contracting/discount oppos etc anoth jak
like
medicaid market state enough money keep
demand like budget constraint caus issu hit number
medicaid come state level
pipelin bare compar large-cap peer simtuzumab
discontinu pancreat cancer data quit neg
indic also challeng
thought gild hcv franchis
think stock grind higher hcv script start flatten
case street would perceiv franchis stabl
greater comfort around whether treatment pool hit bottom investor
unsur whether hcv revenu acceler deceler recov
stabil howev think script start stabil perhap therebi
signal bottom make stock attract valu investor shift
investor focu beyond hcv franchis could help regrow earn
next year
manag look rang scenario built model countri
countri patient number rang per month around
last quarter howev quarter uniqu event new payor plan va
open epclusa launch etc make establish baselin difficult
determin ultim manag would want see coupl quarter stabil
patient add well balanc privat payors/medicare/medicaid/va
feel comfort equilibrium reach
page
pleas see import disclosur inform page report
treat sof-bas regimen time
chart harvoni sovaldi epclusa script project
page
pleas see import disclosur inform page report
chart hcv histor project script trend
page
pleas see import disclosur inform page report
page
pleas see import disclosur inform page report
thought gild hiv franchis
next year hiv make total
revenu remain durabl franchis help better tail visibl
strong b/f/taf launch would help support sotp hiv hcv
though unlik occur model suggest floor hiv due gsk
competit declin post mean downsid
fairli limit big pictur
expect gsk gemini data show non-inferior look
numer wors smaller single-arm phase ii investig trial
use gsk doublet show healthier patient develop
resist dtg vs resist bic cloud dtg overal safeti
large-scal phase think could case issu
patient complet compliant regimen least year
see posit b/f/taf drug co-formul singl pill
singl co-pay vs two copay drug favor renal bone
profil serv larger popul hypersensitivity/cv risk known
low resist barrier gsk recent label revis safeti issu
warn section risk hepatox liver tox dtg may chang
overal risk/benefit use give advantag b/f/taf
balanc side although b/f/taf strong launch support
posit view kol would note expect somewhat high
new triplet provid mostli increment benefit genvoya genvoya
big chang alreadi gsk could creat price risk combin
cheaper compar combin pill overal see hiv
durabl long-tail busi like flat grow longer-
page
pleas see import disclosur inform page report
feb pdufa b/f/taf
bictegravir once-daili oral pill combin emtriva ftc
taf make single-tablet three-drug regimen call b/f/taf
unboost integras inhibitor ini bictegravir confer sever characterist
efficaci insti-associ resist integras strand transfer inhibitor
high barrier resist
compel toler safeti gener date
co-formul singl pill f/taf mean singl co-pay
may gild four bictegravir phase studi met primari
object non-inferior enabl submit nda june
juli b/f/taf show high rate virolog suppress
treatment-emerg resist week treatment-nav adult patient
virolog suppress adult patient switch regimen
share data two treatment nave studi ia confer hiv
scienc pari juli
also share updat data one adult switch studi oct idweek
togeth dataset support nda submiss b/f/taf use
prioriti review voucher june shorten pdufa date feb
chart size b/f/taf
chart list b/f/taf phase studi
inferior triumeq dtg f/taf studi
juli report two phase studi result b/f/taf
treatment-nav patient studi show non-inferior two
studi gsk triumeq vs
studi gsk dolutegravir backbon f/taf vs
non-inferior numer littl lower primari
endpoint data basic similar eye physician doc
consult suggest number differ gener similar
bullish investor hope numer higher gsk
page
pleas see import disclosur inform page report
trialindicationregimenpatientsstatusstudi treatment naveb/f/taf vs triumeq data report juli treatment naveb/f/taf vs dtg f/taf dolutegravir descovi data report juli switchfrom data report may switchfrom boost pi drv atv data report oct switchfrom current on-going
specif play manag commentari convers investor
realli signific expect either way given arm potent
chart virolog outcom week studi b/f/taf vs
chart virolog outcom week studi b/f/taf vs
safeti toler also basic similar differ
appear clinic modest consist w/ doc feedback good regimen
page
pleas see import disclosur inform page report
treatment descriptiontreatmentcomparatordrug armsb/f/taftriumeq evalu patient rna level less copies/ml week chang estim glomerular filtrat week ml/minpati initi lipid-low agent descriptiontreatmentcomparatordrug armsb/f/tafdtg f/tafevalu patient rna level less copies/ml week chang estim glomerular filtrat week ml/minpati initi lipid-low agent
simplic single-tablet b/f/taf best option versu use gsk
abacavir two pill dtg plu f/taf
b/f/taf well toler gener treatment emerg resist
studi b/f/taf vs discontinu
vs gsk due non-relev event arm wherea gsk
higher due actual ae event
studi note toler benefit b/f/taf gsk
higher nausea gi sleep-rel event base patient report
ultim phase result good get new pill
approv market data surpris either way
compar regimen alreadi known potent strong
discuss exist genvoya alreadi strong start swap
mani patient new b/f/taf mostli great new patient start drug
less swap drug per se sinc exist regimen test alreadi good
also share final data switch studi idweek octob
believ data help solidifi valu proposit b/f/taf allow
hiv patient exist therapi switch triumeq bypass boost proteas
inhibitor cobicistat remind triumeq contain abacavir known
studi virolog outcom week rna non-
switcher vs switcher b/f/taf base fda snapshot algorithm
chart virolog outcom week studi switcher
b/f/taf vs boost drv atv nrti
switch b/f/taf non-inferior maintain baselin proteas
page
pleas see import disclosur inform page report
treatment descriptiontreatmentcomparatordrug armsb/f/taf switch sbr evalu patient rna level less copies/ml week chang estim glomerular filtrat week ml/minpati initi lipid-low agent stay baselin regimen boost drv atv
subject arm rna copi
patient develop resist b/f/taf wherea one patient stay
compar arm week instanc mild headach
preval b/f/taf though mostli transient low
arm less patient discontinu due ae event
b/f/taf patient discontinu renal advers event versu one patient
stay baselin regimen
statist signific improv triglycerid total cholesterol
seen patient switch b/f/taf
thought b/f/taf
believ bictegravir show similar efficaci dolutegravir latter
alreadi well-toler drug howev believ b/f/taf could
offer benefit triumeq gsk/viiv dolutegravir-
b/f/taf theoret yield hypersensit cardiovascular
side effect comparison triumeq contain abacavir gener safeti risk
myocardi infarct mi stroke section label discuss
prospect observ studi suggest higher risk mi section
note gsk pool data show excess risk black-box
warn abacavir hypersensit
b/f/taf serv larger popul elimin booster
pertain approv hiv combin regimen target hbv patient
bottom line phase dataset treatment-nav switch studi
surpris us consist overal invest thesi
also note gsk phase gemini studi also watch gemini
use regimen versu studi use could
present long-term market share risk though assum numer lower
virolog reduct vs
two treatment-nav trial double-blind studi patient
per trial random receiv b/f/taf vs abacavir/ dolutegravir/
lamivudin triumeq studi b/f/taf vs dolutegravir
descovi dtg ftc/taf studi primari endpoint proport
patient rna level copies/ml week lower bound
confid interv ci non-inferior
trial stay exist regimen triumeq switch b/f/taf studi
stay exist regimen either darunavir atazanavir boost
proteas inhibitor plu nucleosid backbon switch b/f/taf
studi primari endpoint proport hiv patient rna level
copi week lower bound confid interv
non-inferior switch studi random
page
pleas see import disclosur inform page report
chart summari bictegravir phase studi treatment naiv adult patient
chart summari bictegravir phase studi virologically-suppress adult patient
page
pleas see import disclosur inform page report
trialstudi treatment studi treatment phase phase iiiphas iiiinitiatednov data releas estimate complet data releas estimate complet /emtricitabin ftc /tenofovir taf bictegravir /emtricitabin ftc /tenofovir taf dose dtg /abacavir /lamivudin dolutegravir dtg emtricitabin ftc /tenofovir taf dose durationat least weeksat least adultstreat adultspurposedemonstr non-inferior b/f/taf vs triumeqdemonstr non-inferior b/f/taf vs dtg descovyoth design cirteria -- inclus criteria day prior therapi except use prep/pep day prior therapi except use prep/peprna level copies/ml screeningrna level copies/ml screeningadequ renal function glomerular filtrat rate renal function glomerular filtrat rate screen allel -- -primari endpoint subject plasma rna copi ml week subject plasma rna copi ml week endpoint subject plasma rna copi ml week subject plasma rna copi ml week subject plasma rna copi ml week subject plasma rna copi ml week hiv-rna week hiv-rna week cell count week cell count week hip bone minder densiti week spine bone minder densiti week completionmay switch studi studi switch studi phase phase iiiphas iiiinitiatednov data releas estimate complet data releas estimate complet /emtricitabin ftc /tenofovir taf bictegravir /emtricitabin ftc /tenofovir taf dose dtg /abacavir /lamivudin atazanavir atv /boost darunavir drv /boost ftc/tdf atv drv durationat least weeksat least therapi adultsmainten therapi adultspurposedemonstr non-inferior b/f/taf vs triumeqdemonstr non-inferior b/f/taf vs boost piother design cirteriaswitch triumeq b/f/tafswitch boost atv drv plu ftc/tdf b/f/tafinclus criteriacurr receiv triumeq fdc current receiv boost atv drv regimen month stabl rna level copies/ml screen stabl month previou use instiadequ renal function glomerular filtrat rate renal function glomerular filtrat rate resist ftc tenofovir dtg resist ftc tenofovir expect yearprimari endpoint subject plasma rna copi ml week subject plasma rna copi ml week endpoint subject plasma rna copi ml week subject plasma rna copi ml week cell count week cell count week hip bone minder densiti week spine bone minder densiti week completionmay boost pi includ ritonavir rtv cobi
statu sword gemini studi
flag potenti risk competitor gsk/viiv
integras inhibitor dolutegravir dtg
combin either rilpivirin rpv dtg/rpv approv juluca
novemb follow posit result two phase switch studi
current phase studi
treatment-nav patient data regulatori submiss expect
design use
gener two-drug regimen like dolutegravir potenti
challeng standard therapi
result lower cost toxic pill burden
market recept new treatment advanc
improv ae profil target age hiv patient co-morbid
viiv dolutegravir second-gener drug cabotegravir long-act
shown clinic efficaci high genet barrier excel safeti profil
gsk/ viiv report posit phase data switch studi
hiv patient headlin result report
decemb detail studi result present croi februari
dtg/rpv two-drug regimen achiev non-inferior viral suppress copies/ml
rna week versu three- four-drug regimen commonli report
nasopharyng headach diarrhoea upper respiratori tract
infect suggest safeti profil dtg rpv consist
respect label
sword studi enabl gsk/viiv submit regulatori applic
ema fda june partner use recently-acquir prioriti
review voucher conjunct nda file shorten pdufa date
month follow receipt applic fda fda approv
dtg/rpv combin juluca novemb approv
expect juluca alreadi includ eac european aid
clinic societi guidelin suppress switch
chart dolutegravir snapshot outcom week pool
page
pleas see import disclosur inform page report
treatment-nav patient data
expect file
addit sword gsk plan report phase data two-
drug combin studi treatment-nav patient
follow regulatori file studi investig
treatment infect treatment-nav adult patient
gemini phase random multicentr non-inferior trial evalu efficaci
vs dtg tdf/ftc week patient rna
copies/ml baselin primari endpoint non-inferior antivir activ
measur proport particip plasma rna week
chart summari viiv phase gemini sword studi
page
pleas see import disclosur inform page report
trialsword switch studi gemini glaxosmithklin gsk glaxosmithklinephas nda/ema file submittedphas iiiiinitiatedcomplet on-going on-going recruit statusongo recruit recruitingregimendolutegravir dtg rilpivirin rpv dolutegravir dtg lamivudin nrti ini nrti nnrti nrti pidolutegravir dtg tenofovir tdf /emtricitabin ftc dose mgstudi total indicationmainten therapi adultstreat non-inferior dtg rpv vs demonstr non-inferior dtg vs dtg tdf/ftcother design cirteriaswitch visit group start dtg rpv therapi week stratifi screen rna level cell countinclus criteriamust uninterrupt current regimen day prior therapi antiretrovir agent rna level copies/ml screeningrna level copies/ml screeningprimari endpoint subject plasma rna copi ml week subject plasma rna copi ml week endpoint subject plasma rna copi ml week subject plasma rna copi ml week rna cell count week cell count week patient diseas progressionincid resist dtg rpv incid resist dtg tdf/ftcsafeti toler safeti toler biomark renal bone cv week renal bone week lipid week lipid week abnorm week grade abnorm week life week concentr dtg rpv -clinicaltri gov sword sword gemini gemini completionsep expect readout per gsk decemb present data croi feb expect launch per current antiretrovir regimenntri nucleosid revers transcriptas inhibitorsini integras inhibitornnrti non-nucleosid revers transcriptas inhibitorpi proteas inhibitor
paddl studi support rational
gemini week data juli ia
viiv huesp foundat ran phase iv pilot open-label singl
arm exploratori trial paddl pilot antiretrovir design
dolutegravir lamivudin data report ia confer
juli phase iv studi evalu antivir efficaci safeti toler
once-daili dtg treatment-nav adult trial enrol
two cohort hiv patient hiv rna load
copies/ml count cells/ml viral load measur baselin day
week
data posit treatment-nav patient limit
even though patient paddl studi achiev viral load
copies/ml week maintain patient week
paddl studi limit requir data studi
paddl singl arm studi recruit small sampl size
exclud patient viral load copies/ml
exclud screen count
data insuffici justifi enrol phase patient high
genotyp patient pdvf show revers transcriptas rt
mutat integras amplifi
european aid confer octob viiv report initi
result show nave patient viral load copies/ml
week respons maintain thereaft count rose averag
cell week cell week one report incid
grade headach grade aros first week therapi
seriou seen across week accord public research
note random fulli power trial must confirm preliminari
viiv report posit result aid confer august
observ failur rate week achiev primari
endpoint hiv load copi one subject commit suicid due stress
emot trauma deem unrel studi medic anoth
show low level virolog failur week patient consid
page
pleas see import disclosur inform page report
failur howev follow week resuppress
without chang antivir regimen major toler toxic issu
chart protocol-defin virolog failur seen patient
count failur week later re-suppress
ia confer juli viiv report result
patient result includ extens phase
patient complet week maintain plasma
rna level copies/ml
mean increas cells/mm chang week
new virolog failur aid defin ill sae treatment
instanc grade laboratori abnorm seen high cholesterol
proteinuria deem unrel
chart viral load baselin week copies/ml
page
pleas see import disclosur inform page report
phase ii studi build
paddl week result juli ia
phase ii pilot studi built paddl result
enrol treatment-nav patient viral load
elig criteria art drug nave viral load vl copies/ml pre-
specifi enrol vl copies/ml evid
rt integras proteas resist mutat genotyp perform
primari endpoint virolog success rate week
secondari endpoint efficaci comparison patient baselin viral load
emerg integras rt resist upon virolog failur
safeti toler impact minor drug-resist variant drug
cpm week confirm vl cpm at/aft week
chart patient disposit week
result show show virolog success rate
patient patient specif rna load copies/ml seen
patient cpm baselin patient
cpm baselin total virolog failur patient
virolog data primarili due discontinu lost follow-up pregnanc
patient failur uncommon associ sub-optimal adher
patient met pdfv definit one emerg mixtur
result support gemini studi provid data resist
barrier
page
pleas see import disclosur inform page report
